Therefore, by inhibiting BTK, Ibrutinib reduces the proliferation of these aberrant B cells, thereby helping to manage leukemia consequently, reducing tumors related to CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.